Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2. Please direct any questions regarding coding to the payer being billed.
A Multigene Test Could Cost Effectively Help Extend Life Expectancy For Women At Risk Of Hereditary Breast Cancer Value In Health
Antoniou A et al.
Brca testing cpt. A relative with cancer has a diagnostic blood test to see if they have a cancer risk gene this must happen before any healthy relatives are tested. Genetic tests addressed in this document include BRCA1 and BRCA2 mutations and large genomic rearrangements of DNA in the BRCA1 and BRCA2 genes BRACAnalysisRearrangement Test BART. CPT coding is the sole responsibility of the billing party.
Aetna considers germline BRCA testing eg BRACAnalysis CDx medically necessary for women with locally advanced or metastatic human epidermal growth factor receptor 2 HER2-negative breast cancer who are being considered for talazoparib Talzenna. Contact CMBP genetics services at 800-345-4363 to coordinate testing. This document addresses BRCA genetic testing DNA testing for individuals who are at higher than average risk for the development of cancer.
MultiSite 3 BRACAnalysis. COMMONLY ORDERED TEST AND CPT CODE CHART updated 2182021 Test CPT TAT days Specimen Type BRCA1 and BRCA2 Ashkenazi Jewish 3-Mutation Panel 81212 G0452 5-10 PB BRCA1 and BRCA2 Sequencing and Full Deletions Duplications 81162 G0452 5-10 PB BRCA1 and BRCA2 Full Deletion Duplication 81164 G0452 5-10 PB Breast Cancer Risk Assessment. Their result will be ready 4 to 8 weeks later.
Evidence in the published peer-reviewed scientific literature indicates that BRCA1 and BRCA2 genetic testing is appropriate for a specific subset of adult individuals who have been identified to be at high risk for hereditary breast and ovarian cancers. Results of the BRCA testing enable to provide an individualized medical management for the high risk population. A BRCA ssure clinical questionnaire should be submitted with specimens.
If your relatives test is positive you can have the predictive genetic test to see if you have the same faulty gene. Genetic testing for just BRCA1. Breast Cancer Gene BRCA Testing Prior Authorization Submit your request by calling the Provider Services phone number on the members health plan ID card.
The format is GTR000000011 with a leading prefix GTR followed by 8 digits a period then 1 or more digits representing the version. Each Test is a specific orderable test from a particular laboratory and is assigned a unique GTR accession number. In addition there are other genes that may have mutations that can contribute to a familys risk for cancer.
Identify at-risk individuals and family members counsel on the underlying causes of the pattern of cancers in the family. When a laboratory updates a registered test a new version number. Genetic testing for BRCA1 and BRCA2 mutations has been available to the public since 1996.
Therefore effective for dates of service on or after December 29 2014 BRCA1 and BRCA2 genetic testing for a familial mutation submitted with CPT codes 81215 and 81217 will be denied as statutorily excluded services. Or Risk assessment of other cancers. 25810515139620 Furthermore several specialty organizations including NCCN American College of Medical Genetics.
Genetic testing for BRCA1 andor BRCA2 is unproven and not medically necessary for all other indications including. Genetic testing for BRCA1 and BRCA2 mutations cannot detect 100 of these mutations. Thus even with a negative result there is very small chance that there is a BRCA1BRCA2 gene mutation present that was not identified by the testing method utilized.
BRCA2 genes are responsible for the cancer susceptibility in the majority of HBOC families especially if ovarian cancer or male breast cancer are features. Or Confirmation of direct to consumer genetci testing without meeting any of the proven indications above. V2634 Testing of male for genetic disease carrier status Z31440 Encounter of male for testing for genetic disease carrier status for procreative management V8401 Genetic susceptibility to malignant neoplasm of breast BRCA1 or BRCA2 mutations confirmed by molecular susceptibility testing for breast cancer genetic mutation in the TP53 or PTEN genes Li-Fraumeni.
Screening for cancer risk for individuals not listed in the proven indications above.
